POS1051 SECUKINUMAB IMPROVES PHYSICAL FUNCTION AND INHIBITS STRUCTURAL DAMAGE IN PsA PATIENTS WITH SUSTAINED REMISSION OR LOW DISEASE ACTIVITY: RESULTS FROM A PHASE 3 STUDY

Background: Disease Activity Index for Psoriatic Arthritis (DAPSA) or the minimal disease activity (MDA) are considered defining remission (REM) low (LDA) in secukinumab (SEC) treated patients (pts) with PsA (Psoriatic Arthritis). 1 Currently, limited SEC data available on pts achieving sustained REM clinical trials real-world evidence, using these stringent criteria. Objectives: To report an exploratory analysis achievement of REM/LDA and impact structural outcomes, physical function health-related quality life (HRQoL) FUTURE 5 study ( NCT02404350 ). Methods: is a randomised, double-blind, placebo-controlled 2-year phase 3 trial active PsA. 2 Pts randomised to 150 mg could be escalated 300 from Week (Wk) 52 104, based investigators’ judgement. The were categorised as either not REM/LDA, it once only which was defined who achieved between Wks 24-52 maintained same response at least next 6 visits (visit every 8 Wks). Of did achieve (VLDA, DAPSA REM, MDA, LDA+REM) Wk 24 52, relationship absence proportion non-radiographic progression (assessed van der Heijde [mTSS]), (health assessment questionnaire disability index [HAQ-DI]), short form-36 component score [SF-36 PCS]) assessed. Results: In total, 996 one 4 treatment groups: loading dose (LD; N=222), LD (N=220), no (NL; placebo (N=332). baseline characteristics comparable across groups. Majority MDA/sustained LDA+REM (Figure 1). whether visit consistently, showed improved SF36-PCS 104. A high show radiographic 104 irrespective category (Table Conclusion: majority able LDA. Sustained LDA/REM associated HRQoL, inhibition damage progression. References: [1]Coates LC, et al. J Rheumatol. 2018;46(1):38–42. [2]Van D, Rheumatology . 2020;59(6):1325–1334. [3]Coates L, [0353]. Rheumatol 2020;72 (suppl 10). Figure 1. Proportion VLDA/MDA/DAPSA REM/DAPSA REM+LDASus-tained if out (every weeks), respectively. DAPSA, Arthritis; LD, dose; LDA, Low Activity; Minimal N, number assessed both 104; NL, without remission; SEC, secukinumab; VLDA, Very Table Percentage vdH-mTSS (change ≤0.5) by status LDA composite indices, n (% ) Treatment group No MDA 64 (75.3) 16 (80.0) 76 (86.4) NL 56 (75.7) 15 (78.9) 69 (82.1) 58 (79.5) 19 (95.0) 100 (94.3) VLDA 108 (78.8) (83.3) 30 (88.2) 95 (75.4) 13 (81.3) 32 (91.4) 115 (84.6) 17 (94.4) 45 (100.0) 77 (76.2) 11 (78.6) 46 (92.0) 65 (71.4) 10 (76.9) 50 (87.7) 82 (83.7) 14 (93.3) 63 (96.9) + 29 (70.7) (84.2) 80 23 (71.9) (75.0) 79 (79.0) 39 (88.6) 21 (84.0) 97 (89.0) twice n, evaluable patients; vdH-mTSS, Heijde- modified total Sharp Disclosure Interests: Laura C Coates Consultant of: Abbvie, Amgen, Biogen, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer UCB, Grant/research support from: Novartis Pfizer, Philip Mease Speakers bureau: AbbVie, BMS, Genentech, SUN Pharma, SUN, Dafna D Gladman Eli Sandra Navarra Astra-Zeneca, Astellas, Weibin Bao Shareholder Employee Corine Gaillez Novartis.